A Novel Laboratory-Based Model to Predict the Presence of Obstructive Coronary Artery Disease.

Commonly used tools to assess the probability of obstructive-coronary artery disease (CAD) were derived based on Caucasian cohorts, with their performance in China is still unknown.

Furthermore, most were established based on non-laboratory variables, contributing to the limited predictive ability to some extent. Thus, we developed and internally validated a laboratory-based model with data from a Chinese cohort of 8963 inpatients, with suspected stable chest pain, referred to catheter-based coronary angiography (CAG) from September 2007 to April 2019, and then compared the present model’s performance with the four most commonly used prediction tools, Coronary Artery Disease Consortium 1/2 Score (CAD1/2), Duke clinical score (DCS), and Diamond-Forrester score (DF).

The final model was developed by random forest method, including 8 predictors derived from 70 variables. Five-fold cross-validation was performed to evaluate the model’s prediction accuracy. In the external validation set, the present model showed a superior area under the receiver-operating curve (0.816), followed by DCS (0.66), CAD2 (0.61), CAD1 (0.59) and at last DF (0.58), respectively.

Furthermore, the present model correctly classified 74.4% of obstructive-CAD patients as high-risk, and correctly classified more than one third of non-obstructive-CAD patients as low-risk.

The present model’s net reclassification improvement (NRI) showed a significant positive reclassification over CAD1 (NRI = 0.60, P < 0.001), DF (NRI = 0.59, P < 0.001), CAD2 (NRI = 0.57, P < 0.001), and DCS (NRI = 0.43, P < 0.001). Decision curve analysis demonstrated that the present model provided a larger net benefit compared with CAD1/2, DCS, and DF.

UCN-02

HY-108262 1mg
EUR 727

TA-02

HY-100115 10mM/1mL
EUR 404

UCN-02

U006-1MG 1 mg
EUR 331

UCN-02

U006-5MG 5 mg
EUR 1082

TA 02

B4924-10 10 mg
EUR 299

TA 02

B4924-5.1 10 mM (in 1mL DMSO)
EUR 177

TA 02

B4924-50 50 mg
EUR 1095

PU 02

B5687-10 10 mg
EUR 229

PU 02

B5687-25 25 mg
EUR 476

PU 02

B5687-5 5 mg
EUR 144

PU 02

B5687-50 50 mg
EUR 806

UCN-02

C4829-1 1 mg
EUR 460
Description: UCN-02 is a derivative of staurosporine and a stereoisomer of UCN-01, which has been first isolated from a high staurosporine-producing Streptomyces culture as a minor co-metabolite [1]. UCN-02 is protein kinase C inhibitor [1].

UCN-02

C4829-5 5 mg
EUR 1488
Description: UCN-02 is a derivative of staurosporine and a stereoisomer of UCN-01, which has been first isolated from a high staurosporine-producing Streptomyces culture as a minor co-metabolite [1]. UCN-02 is protein kinase C inhibitor [1].

TA-02

B1215-25
EUR 566

TA-02

B1215-5
EUR 185

ELX-02 disulfate

HY-114231B 5mg
EUR 567

ELX-02 sulfate

HY-114231C 10mg
EUR 911

OXF BD 02

B4918-10 10 mg
EUR 350

OXF BD 02

B4918-50 50 mg
EUR 1314

1961358-02-0

TBW00994 10mg Ask for price

145867-02-3

TBZ1279 unit Ask for price

VX-222 (VCH-222, Lomibuvir)

A4032-10 10 mg
EUR 305
Description: VX-222, a derivative of thiophene-2-carboxylic acid, is a potent non-nucleoside inhibitor (NNI) of the hepatitis C virus (HCV) RNA polymerase, an enzyme regulating RNA synthesis by a de novo-initiated mechanism or by extension from a primed template.

VX-222 (VCH-222, Lomibuvir)

A4032-100 100 mg
EUR 1186
Description: VX-222, a derivative of thiophene-2-carboxylic acid, is a potent non-nucleoside inhibitor (NNI) of the hepatitis C virus (HCV) RNA polymerase, an enzyme regulating RNA synthesis by a de novo-initiated mechanism or by extension from a primed template.

VX-222 (VCH-222, Lomibuvir)

A4032-5 5 mg
EUR 189
Description: VX-222, a derivative of thiophene-2-carboxylic acid, is a potent non-nucleoside inhibitor (NNI) of the hepatitis C virus (HCV) RNA polymerase, an enzyme regulating RNA synthesis by a de novo-initiated mechanism or by extension from a primed template.

VX-222 (VCH-222, Lomibuvir)

A4032-50 50 mg
EUR 838
Description: VX-222, a derivative of thiophene-2-carboxylic acid, is a potent non-nucleoside inhibitor (NNI) of the hepatitis C virus (HCV) RNA polymerase, an enzyme regulating RNA synthesis by a de novo-initiated mechanism or by extension from a primed template.

Monoclonal LST1 Antibody (clone LST1/02), Clone: LST1/02

APR12482G 0.05mg
EUR 484
Description: A Monoclonal antibody against Human LST1 (clone LST1/02). The antibodies are raised in Mouse and are from clone LST1/02. This antibody is applicable in WB and IHC-P, ICC, IP

JH-VIII-157-02

HY-112140 10mM/1mL
EUR 744

Anti-07/02/07

STJ501223 100 µg
EUR 476

VX-222

HY-75800 10mM/1mL
EUR 201

VX-222

E1KS1480 5mg
EUR 874

QX 222

B6565-10 10 mg
EUR 171

QX 222

B6565-50 50 mg
EUR 470

VX-222

B2207-25
EUR 675

VX-222

B2207-5
EUR 207

5-IAF [5-Iodoacetamidofluorescein] *CAS 63368-54-7*

222 25 mg
EUR 219

miRZip-222 anti-miR-222 microRNA construct

MZIP222-PA-1 Bacterial Streak
EUR 684

Monoclonal HLA-E Antibody (clone MEM-E/02), Clone: MEM-E/02

AMM02314G 0.05mg
EUR 484
Description: A Monoclonal antibody against Human HLA-E (clone MEM-E/02). The antibodies are raised in Mouse and are from clone MEM-E/02. This antibody is applicable in WB and IHC-P

Monoclonal HLA-E Antibody (clone MEM-E/02), Clone: MEM-E/02

AMM01781G 0.05mg
EUR 484
Description: A Monoclonal antibody against Human HLA-E (clone MEM-E/02). The antibodies are raised in Mouse and are from clone MEM-E/02. This antibody is applicable in WB and IHC-P

Septin 2 (Sep-02) Antibody

20-abx306884
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Septin 2 (Sep-02) Antibody (HRP)

20-abx306885
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Septin 2 (Sep-02) Antibody (FITC)

20-abx306886
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Septin 2 (Sep-02) Antibody (Biotin)

20-abx306887
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

MAP2K3 (Ab-222) Antibody

CSB-PA084775-
EUR 335
Description: A polyclonal antibody against MAP2K3 (Ab-222). Recognizes MAP2K3 (Ab-222) from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF;WB:1:500-1:3000, IF:1:50-1:200

MAP2K3 (Ab-222) Antibody

CSB-PA084775-100ul 100ul
EUR 316
Description: A polyclonal antibody against MAP2K3 (Ab-222). Recognizes MAP2K3 (Ab-222) from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF;WB:1:500-1:3000, IF:1:50-1:200

BTK (Ab-222) Antibody

33121-100ul 100ul
EUR 252

BTK (Ab-222) Antibody

33121-50ul 50ul
EUR 187

MAP2K3 (Ab-222) Antibody

33236-100ul 100ul
EUR 252

MAP2K3 (Ab-222) Antibody

33236-50ul 50ul
EUR 187

MEK1 (pS218 / 222) Antibody

abx031877-400ul 400 ul
EUR 523

MEK1 (pS218 / 222) Antibody

abx031877-80l 80 µl
EUR 286

MAPK3 (pY205 / 222) Antibody

abx333481-100ul 100 ul
EUR 467

rno-miR-222 Primers

MP-r00149 150 ul / 10 uM
EUR 176

hsa-miR-222 Primers

MPH01282 150 ul / 10 uM
EUR 121

mmu-miR-222 Primers

MPM00254 150 ul / 10 uM
EUR 121

Cytokeratin 222 Pseudogene antibody

70R-4160 50 ug
EUR 467
Description: Rabbit polyclonal Cytokeratin 222 Pseudogene antibody raised against the N terminal of KRT222P

Z-IETD-AFC *CAS 219138-02-0*

13425 5 mg
EUR 158

Indo-1, AM *CAS 112926-02-0*

21030 1 mg
EUR 132

Indo-1, AM *CAS 112926-02-0*

21033 50 mg
EUR 2181

Mouse Anti Escherichia Coli 02 Monoclonal Antibody

DMABT-51244ME 0.2 mg
EUR 741

Phospho-MAPK3 (Tyr205/222) Antibody

CSB-PA213371-
EUR 335
Description: A polyclonal antibody against Phospho-MAPK3 (Tyr205/222). Recognizes Phospho-MAPK3 (Tyr205/222) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:1000

Phospho-MAPK3 (Tyr205/222) Antibody

CSB-PA213371-100ul 100ul
EUR 362
Description: A polyclonal antibody against Phospho-MAPK3 (Tyr205/222). Recognizes Phospho-MAPK3 (Tyr205/222) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:1000

Polyclonal MEK1 Antibody (S218/222)

APR06041G 0.1ml
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human MEK1 (S218/222). This antibody is tested and proven to work in the following applications:

MKK1 / 2 (pS218 / 222) Antibody

20-abx134438
  • EUR 314.00
  • EUR 467.00
  • EUR 203.00
  • 100 ul
  • 200 ul
  • 30 ul

Transmembrane Protein 222 (TMEM222) Antibody

20-abx302905
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

MAP2K1 / MAP2K2 (pS218 / 222) Antibody

20-abx329018
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug

Anti-ZDHHC1 (aa213-222) antibody

STJ72388 100 µg
EUR 260

BTK (Ab-222) Conjugated Antibody

C33121 100ul
EUR 397

MAP2K3 (Ab-222) Conjugated Antibody

C33236 100ul
EUR 397

hsa-miR-222 miRNA Inhibitor

MIH01588 2 x 5.0 nmol
EUR 176

mmu-miR-222 miRNA Inhibitor

MIM01544 2 x 5.0 nmol
EUR 176

rno??miR-222 miRNA Inhibitor

MIR01333 2 x 5.0 nmol
EUR 176

mmu-miR-222 miRNA Antagomir

MNM01544 2 x 5.0 nmol
EUR 329

rno??miR-222 miRNA Antagomir

MNR01333 2 x 5.0 nmol
EUR 329

hsa-miR-222-3p Primers

MPH02352 150 ul / 10 uM
EUR 121

hsa-miR-222-5p Primers

MPH02353 150 ul / 10 uM
EUR 121

mmu-miR-222-3p Primers

MPM01029 150 ul / 10 uM
EUR 121

mmu-miR-222-5p Primers

MPM01030 150 ul / 10 uM
EUR 121

rno-miR-222-3p Primers

MPR00529 150 ul / 10 uM
EUR 176

rno-miR-222-5p Primers

MPR00530 150 ul / 10 uM
EUR 176

hsa-miR-222 miRNA Antagomir

MNH01588 2 x 5.0 nmol
EUR 329

Cytokeratin 222 Pseudogene Blocking Peptide

33R-2575 100 ug
EUR 180
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KRT222P antibody, catalog no. 70R-4160

MEK1/2 antibody (Ser218/222)

70R-34260 100 ug
EUR 327
Description: Rabbit polyclonal MEK1/2 antibody (Ser218/222)

MAPK1/3 antibody (Tyr205/222)

70R-34647 100 ug
EUR 327
Description: Purified Rabbit polyclonal MAPK1/3 antibody (Tyr205/222)

MB-02 Plain plate 2mm thickness 1 set

2393036 15unit
EUR 311
Description: 2 pl at es

Tubulin-alpha (Microtubule Marker); Clone TU-02 (Concentrate)

RA0324-C.1 0.1 ml
EUR 125

Tubulin-alpha (Microtubule Marker); Clone TU-02 (Concentrate)

RA0324-C.5 0.5 ml
EUR 300

Recombinant Human CD93 Protein-6His-ABP tag

CTP-222 100ug Ask for price
Description: A 30 kDa recombinant human CD93 protein Antigen with a N-terminal His6-ABP tag expressed in E. Coli.

Recombinant P. vivax MSP1-cap [His]

DAGA-222 1 mg
EUR 441

HIV-1 gp120 and gp41 Chimeric Antigen (8 kDa, Capture)

DAGF-222 1mg
EUR 681

Rabbit Anti-ACTA1 monoclonal antibody, clone KK10-30

DCABH-222 100 ul
EUR 777

CytoSelect 96-Well Phagocytosis Assay (E. coli, Colorimetric Format)

CBA-222 96 assays
EUR 693
Description: Phagocytosis can be assayed by measuring the engulfment of a cell "substrate". However, traditional assays require tedious cell counting under a microscope. Our CytoSelect 96-Well Phagocytosis Assay, E. coli Substrate provides a more accurate, user-friendly, high-throughput alternative to the standard phagocytosis assay. The assay may be adapted for use with 24-well or 48-well plates.

IL-17F Recombinant Protein

11-222 0.05 mg
EUR 595.25
Description: Interleukin-17F (IL17F) is also known as Interleukin-24 (IL24), Cytokine ML-1, is a secreted disulfide-linked homodimer which belongs to the IL-17 family. There are at least six members of the IL-17 family in humans and in mice: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25) and IL-17F (also called IL-24). IL-17 represents a family of structurally related cytokines that share a highly conserved C-terminal region but differ from one another in their N-terminal regions and in their distinct biological roles. IL-17F / IL-24 is expressed in activated, but not resting, CD4+ T-cells and activated monocytes. IL17F / Interleukin-24 stimulates the production of other cytokines such as IL-6, IL-8 and granulocyte colony-stimulating factor, and can regulate cartilage matrix turnover. IL17F / IL-24 stimulates PBMC and T-cell proliferation and Inhibits angiogenesis. Defects in IL17F are the cause of familial candidiasis type 6 (CANDF6).

SARS Coronavirus Envelope (HSZ-Cc) Recombinant Protein

20-222 0.1 mg
EUR 605.75
Description: SARS Coronavirus Envelope (HSZ-Cc) Recombinant Protein

TNF-alpha, Soluble Recombinant Protein

90-222 50 ug
EUR 390.5
Description: Tumor necrosis factor (TNF, cachexin or cachectin and formerly known as tumor necrosis factor-alpha) is a cytokine involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute phase reaction. The receptor TNF-R1 is activated by both the membrane-bound and soluble trimeric forms of TNF-alpha, whereas the receptor TNF-R2 only responds to the membrane-bound form of TNF-alpha (MultimericTNF-alpha (Prod. No. AG-40B-0019). Since the MultimericTNF-alpha mimics the membrane-bound form (forms oligomers higher than trimer), it is the only TNF-alpha protein that can activate the TNF-R2. For TNF-R1 activation, either "normal" TNF-alpha or MultimericTNF-alpha can be used.

OTUB2 Recombinant Protein

91-222 0.05 mg
EUR 710.75
Description: Ubiquitin Thioesterase OTUB2 belongs to the peptidase C65 family, functions as a hydrolase that can remove conjugated ubiquitin from proteins in vitro, may plays an important regulatory role at the level of protein turnover by preventing degradation. OTUB2 is expressed at higher levels in the brain.

Sentrin-specific protease 2 Recombinant Protein

92-222 0.05 mg
EUR 311.75
Description: SENP2 is an enzyme that belongs to the peptidase C48 family. SENP2 is a protease that catalyzes two essential functions in the SUMO pathway: processing of full-length SUMO1, SUMO2 and SUMO3 to their mature forms and deconjugation of SUMO1, SUMO2 and SUMO3 from targeted proteins. SUMO1 is a small ubiquitin-like protein that can be covalently conjugated to other proteins. It has been implicated as a down-regulator of CTNNB1 levels and may therefore be a modulator of the Wnt pathway.

In conclusion, the novel model, using 8 laboratory and non-laboratory variables, performed well in risk stratifying patients with suspected chest pain regarding the presence of obstructive-CAD in the present Chinese cohort.